Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

APAri PelcovitsDTDiana O. TreabaPDPatrycja M. Dubielecka

Discussion

Loading...

Member takes

Overview

Spatial analysis reveals differential T cell activation and macrophage involvement in follicular lymphoma, indicating potential for enhanced marshaling with immunotherapies.

Key Points

  • Follicular lymphoma TME demonstrated increased macrophage content and T cell activation during mosunetuzumab therapy, emphasizing its role in treatment efficacy.
  • Differential gene expression highlighted T cell infiltration and activation within the border zone, aligning with patient outcomes.
  • Using multiplex immunofluorescence and spatial transcriptomics, four spatial domains were defined to analyze T cell interactions across patient tumors.
  • Key findings suggest exploration of BsAb combinations with agents targeting T cell or macrophage functions could enhance therapy outcomes.

Cite This Study

Pelcovits et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db19https://doi.org/10.1182/blood-2025-5327
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma2025
  2. 2Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis2025 · 2 citations
  3. 3Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy2025
  4. 4Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial2025 · 1 citations
  5. 5Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy2025